Squamous Cell Carcinoma of Oral Cavity Clinical Trial
Official title:
Assessing Efficacy of Neoadjuvant Chemoradiotherapy as a Treatment Plan for Patients With Stage IVa Oral Cancer.
Oral cancer is the single largest cancer in males in India. 90-95% cases of oral cancer are Squamous cell carcinomas and many of them present at late stages (T3 and above). Treatment of OSCC includes single modality surgery, radiotherapy, or combinations of these modalities with or without systemic therapy. For unresectable cases, radiotherapy and/or chemotherapy is the treatment modality. Efficacy of neoadjuvant chemoradiotherapy for resectable stage IV tumors (late stage) needs to be evaluated to assess its benefit before surgery.
This study will assess the benefit of preoperative adjuvant chemoradiotherapy in patients
with an Stage IVa oral squamous cell carcinoma (OSCC). The study population will consist of
patients who have not been treated previously. Patients satisfying the inclusion-exclusion
criteria will be included in the study after obtaining a valid, written and informed consent.
After reviewing the histopathological report, the patients will be treated as per the study
protocol. The patients will be under regular follow-up with 3 monthly intervals for a period
of one year and 6 monthly period in the following years. At each follow-up, patients will be
evaluated clinically for evidence of locoregional tumor recurrence. The locoregional
recurrence-free survival will be calculated based on the difference between the date of
inclusion and the date of biopsy-proven recurrence. We will also record the overall survival,
parameters like trismus, osteonecrosis and xerostomia. Quality of life will be assessed at a
regular interval of 1 year using the University of Washington Quality of Life Questionnaire
(UW-QOL v.4)
Study protocol:
1. Preoperative radiotherapy over 5 weeks- Dose 180-200cgys per day/ total 4500 cgys
2. Three weekly concurrent chemotherapy with cisplatin 100 mg /m2
3. Initial surgery in leg for Prefabrication of fibula - 2 weeks after starting of
radiotherapy treatment. Delay is required for planning of implant position in the
fibula.
4. Definitive surgical procedure with reconstruction by prefabricated flap, 6 weeks post
radiotherapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03121313 -
Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+
|
Phase 2 | |
| Recruiting |
NCT05992610 -
Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy
|
N/A | |
| Recruiting |
NCT05144698 -
RAPA-201 Therapy of Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05312710 -
Safety and Efficacy of APG-157 in Head and Neck Cancer
|
Phase 2 |